The combination of olaparib and camptothecin for effective radiosensitization
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. The purpose of this study was to investigate the characteristics of the sensitizing effect of olaparib for radiation and CPT in order to support clinical application of this agent. Methods: DLD-1 cells (a human colorectal cancer cell line) and H1299 cells (a non-small cell lung cancer cell line) with differences of p53 gene status were used. The survival of these cells was determined by clonogenic assay after treatment with drugs and X-ray irradiation. The γH2AX focus formation assay was performed to examine the influence of olaparib on induction and repair of double-stranded DNA breaks after exposure to radiation or CPT. Results: A radiosensitizing effect of olaparib was seen even at 0.01 μM. Its radiosensitizing effect after exposure for 2 h was similar to that after 24 h. H1299 cells with depletion or mutation of p53 were more radioresistant than H1299 cells with wild-type p53. However, similar enhancement of radiosensitization by olaparib was observed with all of the tested cell lines regardless of the p53 status. Olaparib also sensitized cells to CPT. This sensitizing effect was seen at low concentrations of olaparib such as 0.01 μM, and its sensitizing effect was the same at both 0.01 μM and 1 μM. The combination of olaparib and CPT had a stronger radiosensitizing effect. The results of the γH2AX focus assay corresponded with the clonogenic assay findings. Conclusion: Olaparib enhanced sensitivity to radiation and CPT at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, PARP inhibitors enhanced the anticancer activity of chemoradiation in CRC cell lines in vitro and in vivo [136,137,138].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“Thus, SSB are converted to DSB during replication after exposure to olaparib [13].”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y., & Bonner, W. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9390 · Cited by 708 · cited 1×
“Therefore, γH2AX is a sensitive and early indicator of DSB in vitro and in vivo [19].”
BackgroundSaleh-Gohari, N., Bryant, H. E., Schultz, N., Parker, K. M., Cassel, T. N., & Helleday, T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7158-7169.2005 · Cited by 333 · cited 1×
“; licensee BioMed Central L Commons Attribution License ( http://creativeco reproduction in any medium, provided the orig [2].”
Background(1993) · PubMed · Cited by 323
(1997) · PubMed · Cited by 238
p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.
Brachman, D. G., Beckett, M., Graves, D., Haraf, D. J., Vokes, E. E., & Weichselbaum, R. R. (1993) · PubMed · Cited by 222
Dungey, F. A., Löser, D. A., & Chalmers, A. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.07.031 · Cited by 220 · cited 2×
“Unrepaired SSB lead to collapse of replication forks that give rise to potentially lethal DSB, leading to radiosensitization [5].”
Background
Research works printed but not linked: 2
- Hall EJ Hall EJ, Giaccia AM DNA strand breaks and chromosomal aberrations Radiobiology for the radiologist, ed 2006 6 Lippincott Williams & Wilkins, Philadelphia 16 29
- Hall EJ Hall EJ, Giaccia AM Repair of radiation damage and the dose-rate effect Radiobiology for the radiologist, ed 2006 6 Lippincott Williams & Wilkins, Philadelphia 60 84
Cited by
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Buckley, A. M., Lynam-Lennon, N., O’Neill, H., & O’Sullivan, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0247-2 · Cited by 254
Olaparib: First Global Approval
Deeks, E. D. (2015) · Drugs · doi:10.1007/s40265-015-0345-6 · Cited by 188
“Olaparib was radiosensitizing (independent of P53 status [25]) in colorectal cancer [25] and lung cancer [25, 26] cell lines, with stronger radiosensitization observed when in combination with the topoisomerase I inhibitor campothecin [25].”
BackgroundCurrent concepts in clinical radiation oncology
Orth, M., Lauber, K., Niyazi, M., Friedl, A. A., Li, M., Maihöfer, C., Schüttrumpf, L., Ernst, A., Niemöller, O. M., & Belka, C. (2014) · Radiation and Environmental Biophysics · doi:10.1007/s00411-013-0497-2 · Cited by 178
“…great potentials in terms of sensitizing tumor cells to irradiation in combined modality approaches (Donawho et al. 2007; Barazzuol et al. 2013; Miura et al. 2012; Chalmers et al. 2004; Senra et al. 2011; Shelton et al. 2013) and are, therefore, tested in clinical trials (Audeh et al. 2010;…”
BackgroundLesueur, P., Chevalier, F., Austry, J.-B., Waïssi, W., Burckel, H., Noël, G., Habrand, J., Saintigny, Y., & Joly, F. (2017) · Oncotarget · doi:10.18632/oncotarget.19079 · Cited by 142
“NSCLC cell lines (H1299) In vitro Olaparib (1 μM) 1,1 to 1,2 Radiosensitization regardless p53 status [74]”
Background
Metadata
- Authors
- Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M.
- Affiliations
- Sapporo Medical University (JP)
- Tokyo Institute of Technology (JP)
- University of Fukui (JP)
- Gunma University (JP)
- Corresponding author
- Sakata, Koh-ichi
- Venue
- Radiation Oncology
- Published
- 2012-04-23
- Volume
- 7
- Issue
- 1
- Pages
- 62-62
- ISSN
- 1748-717X (ISSN-L)
- PMC
- PMC3430568
- OpenAlex
- W2131874020
- Cited by
- 33
- References
- 21
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 3 · 2022: 3 · 2020: 2 · 2019: 2 · 2017: 2 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Radiation Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (22390231, 21689033, 24390286, 24591845)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- camptothecin, radiosensitization, PARP-1 inhibitors, topoisomerase I inhibitor, p53 status, DNA double-strand break repair, γH2AX foci, clonogenic survival, colorectal cancer, non-small cell lung cancer, combination therapy, radiotherapy, DNA damage response, single-strand breaks
- MeSH terms
- Camptothecin, Cell Survival, DNA Repair, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Phthalazines, Piperazines, Radiation-Sensitizing Agents, Cell Line, Tumor, DNA Breaks, Double-Stranded
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The combination of olaparib and camptothecin for effective radiosensitization. https://app.cochat.ai/papers/10.1186/1748-717x-7-62
- The paper
- Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012). The combination of olaparib and camptothecin for effective radiosensitization. Radiation Oncology. https://doi.org/10.1186/1748-717x-7-62
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.